Ganipineni Vijay Durga Pradeep, Jitta Sahas Reddy, Gudiwada Mohan Chandra Vinay Bharadwaj, Jasti Jaswanth Rao, Janga Chaitra, Merugu Bhavyasri, Bandaru Revanth Reddy, Puli Srikanth, Venkata Vikramaditya Samala, Vasavada Advait, Desai Rupak
Department of Medicine, Andhra Medical College, Visakhapatnam 530002, India.
Department of Internal Medicine, Mercy Hospital, Saint Louis, MO 63141, USA.
Healthcare (Basel). 2024 Oct 14;12(20):2037. doi: 10.3390/healthcare12202037.
Pulmonary hypertension (PH) can lead to cardiac failure, thereby significantly affecting life expectancy and quality of life. Due to inadequate disease surveillance and risk assessment, clinical challenges persist despite advances in diagnosis and treatment. We aimed to review the potential of high-sensitivity cardiac troponin (hs-cTn) as a biomarker for predicting outcomes in PH patients. A thorough examination of the PubMed and Google Scholar databases was conducted through March 2023. Studies involving adult PH patients and hsTn as a prognostic indicator of outcomes such as mortality, hospitalization, and disease progression were included, after screening their titles and abstracts. Two independent evaluators extracted data, with the quality assessed using the JBI critical appraisal tool. This review uncovered eight studies that examined the prognostic value of hs-cTn in PH patients. Higher hs-cTn levels were associated with increased mortality and hospitalization rates, according to the studies. The severity of PH, cardiac dysfunction, right ventricular function, and systolic dysfunction were associated with hs-cTn. Multiple studies have demonstrated that hsTn has the potential to identify high-risk PH patients who could benefit from targeted therapies and increased clinical monitoring. This review suggests that hsTn may be a biomarker for PH risk stratification and prognosis. Across PH subtypes, elevated hsTn levels predict poor outcomes. However, large-scale prospective studies are needed to confirm hs-cTn's function in diagnosing pulmonary hypertension and determine its potential value in treatment.
肺动脉高压（PH）可导致心力衰竭，从而显著影响预期寿命和生活质量。由于疾病监测和风险评估不足，尽管诊断和治疗取得了进展，但临床挑战依然存在。我们旨在综述高敏心肌肌钙蛋白（hs-cTn）作为预测PH患者预后生物标志物的潜力。截至2023年3月，我们对PubMed和谷歌学术数据库进行了全面检索。在筛选标题和摘要后，纳入了涉及成年PH患者以及将hsTn作为死亡率、住院率和疾病进展等预后指标的研究。两名独立评估人员提取数据，并使用JBI批判性评价工具评估质量。本综述发现了八项研究，这些研究探讨了hs-cTn在PH患者中的预后价值。根据这些研究，hs-cTn水平升高与死亡率和住院率增加相关。PH的严重程度、心脏功能障碍、右心室功能和收缩功能障碍均与hs-cTn有关。多项研究表明，hsTn有潜力识别可能从靶向治疗和加强临床监测中获益的高危PH患者。本综述表明，hsTn可能是用于PH风险分层和预后评估的生物标志物。在所有PH亚型中，hsTn水平升高均预示预后不良。然而，需要大规模前瞻性研究来证实hs-cTn在诊断肺动脉高压中的作用，并确定其在治疗中的潜在价值。
